ClinicalTrials.gg
Active, not recruitingNCT07020923Updated Nov 13, 2026

Monthly Dosing of Atacicept in IgAN

A Phase 2 interventional study of Atacicept in IgA Nephropathy (IgAN) and Berger Disease, sponsored by Vera Therapeutics, Inc.. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Vera Therapeutics, Inc. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 75 studies in Glomerulonephritis, IGA with a site in United States — 27 open to participants now, 39 under way, 18 of them phase 3. Glomerulonephritis, IGA · United States.

Planned enrollment
32nd of 69
90 · median 72
Started
2025
with 10 others
Phase 2
30 of 75
11 open now
Primary completion
2026-09
later than 5 of 38 live
Registered
58th of 75
by date
Lead sponsor
4 of 75
Vera Therapeutics, Inc.

Among the 75 studies in Glomerulonephritis, IGA with a site in United States, this one is the 32nd largest by planned enrollment of the 69 interventional ones that give a count, is one of 11 that started in 2025, is one of 30 in phase 2, reaches primary completion later than 5 of the 38 other live ones, and was the 58th registered.

Glomerulonephritis, IGA

276 studies on the registry are indexed under Glomerulonephritis, IGA; 107 are open to participants now.

Browse Glomerulonephritis, IGA studies →

Open to participants now

27 of the 75 studies in Glomerulonephritis, IGA with a site in United States are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Glomerulonephritis, IGA with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2, open-label, multicenter, randomized study comprising parallel groups of participants receiving weekly and/or monthly doses of atacicept

Read the detailed description

This Phase 2 study is to explore the effectiveness, safety and tolerability of different dosing regimens of atacicept. Regimens include monthly and weekly dosing.

03

Conditions studied

  • IgA Nephropathy (IgAN)
  • Berger Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have the ability to understand and sign a written form, which must be obtained prior to initiation of study assessments
  • Adult male or female of ≥18 years of age, or as per country specific legally or nationally recognized adult age, who provides written informed consent prior to performing any study assessments
  • Diagnosis of IgAN as demonstrated by renal conducted within 10 years
  • Total urine protein excretion ≥0.75 g per 24-hour or urine protein-to-creatinine ratio (UPCR) ≥0.75 mg/mg based on a 24-hour urine sample
  • ≥30 mL/min/1.73 m2 at screening, as per the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)
  • On a stable prescribed regimen of RASi (angiotensin converting enzyme inhibitor or angiotensin II receptor blocker) for at least 8 weeks that is at the maximum labeled or tolerated dose at screening and from screening to study Day 1

Exclusion criteria

Exclusion Criteria:

  • IgAN secondary to another condition (eg, liver cirrhosis), or other causes of mesangial IgA deposition including IgA vasculitis (ie, Henoch-Schonlein purpura), systemic lupus erythematosus, dermatitis herpetiformis, ankylosing spondylitis
  • Evidence of rapidly progressive glomerulonephritis (loss of ≥50% of within 3 months of screening)
  • Evidence of nephrotic syndrome within 6 months of screening (serum albumin \<3.0 g/dL in association with UPCR >3.5 mg/mg)
  • Renal or other organ transplantation prior to or expected during the study, with the exception of corneal transplants
  • Concomitant chronic renal disease in addition to IgAN (eg, diabetic nephropathy, primary focal segmental glomerulosclerosis, membranous nephropathy, C3 glomerulopathy, lupus nephritis)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Atacicept Arm 1

    Atacicept dose A administered subcutaneous (sc) injection monthly

    Drug: Atacicept

  • Experimental
    Atacicept Arm 2

    Atacicept dose B administered subcutaneous (sc) injection monthly

  • Experimental
    Atacicept Arm 3

    Atacicept dose C administered subcutaneous (sc) injection monthly

  • Experimental
    Atacicept Arm 4

    Atacicept dose D administered subcutaneous (sc) injection weekly

  • Experimental
    Atacicept Arm 5

    Atacicept dose E administered subcutaneous (sc) injection weekly for 24 weeks, followed by monthly sc injections

Interventions

06

What researchers measure

Primary outcomes

  1. Evaluate the effect of atacicept on Gd-IgA1 in patients with IgAN

    Gd-IgA1 levels through Week 24

    Time frame: Up to 24 weeks

Secondary outcomes

  1. To evaluate the safety and tolerability of atacicept at different dosing regimensT

    Incidence of treatment emergent reported Adverse Events (AE)

    Time frame: Baseline until end of study up to Week 24

  2. To evaluate the effect of atacicept on serum immunoglobulins (IgA)

    IgA levels through Week 24

    Time frame: 24 Weeks

  3. To evaluate the effect of atacicept on serum immunoglobulins (IgG)

    IgG levels through Week 24

    Time frame: 24 Weeks

  4. To evaluate the effect of atacicept on serum immunoglobulins (IgM)

    IgM levels through Week 24

    Time frame: 24 Weeks

  5. To evaluate serum PK of atacicept

    Serum concentration of atacicept

    Time frame: Baseline until end of study up to Week 24

07

Study locations

1 site
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2025 to primary completion in Sep 2026, 15 months.

Of 41 phase 2 interventional studies under Glomerulonephritis, IGA, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 50. This study's 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2025
First posted
Jun 13, 2025
StartActual
May 29, 2025
Primary completionActual
Sep 22, 2026
CompletionEst.
Sep 2027
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and date precision
1 update, last Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Minor edits only
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07020923
Lead sponsor
Vera Therapeutics, Inc.
Responsible party
Sponsor
First posted
Jun 13, 2025
Start date
May 29, 2025
Primary completion
Sep 22, 2026
Completion
Sep 2027 (estimated)
Last update
Nov 13, 2026

Study contacts

Zeeshan Khawaja
study director · Vice President, Clinical Development

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TACI receptor-IgG Fc fragment fusion protein

Start the discussion